[Use of recombinant factor VII in Glanzmann thrombasthenia: a case report].
Glanzmann thrombasthenia (TG) is a congenital platelet function disorder characterized by frequent and occasionally severe bleeding events. Treatment is based on platelet transfusion at the time of bleeding. We report a case of GT revealed in the neonatal period, a severe hemorrhagic syndrome refractory to transfusions, treated at the age of 6 years. Activated recombinant factor VII (Novoseven) injections were necessary. The advantages of recombinant activated factor VII in GT patients with platelet antibodies and/or platelet transfusions refractoriness are discussed.
Chabchoub Ben Abdallah
R
R
Service pédiatrie, urgences et réanimation pédiatriques, CHU Hédi Chaker, Route El Ain Km 0.5, Sfax, Tunisia. rim.ben-abdallah@laposte.net
Trabelsi
L
L
Ben Ameur
S
S
Kammoun
F
F
Boukédi
A
A
Ben Salah
M
M
Ben Hlima
N
N
Mahfoudh
A
A
D002648:Child; D015942:Factor VIIa / Q000627:therapeutic use*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D013915:Thrombasthenia / Q000188:drug therapy*
D006490:Hemostatics; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa